• (-)-JQ1 in Precision Epigenetics: Beyond Negative Control Ut

  2026-07-02

  Explore the advanced role of (-)-JQ1, the JQ1 stereoisomer, in precision epigenetics and cancer biology research. This article offers a unique perspective, integrating recent mechanistic insights and best practices for BET bromodomain inhibitor controls.

• Leveraging Niclosamide for STAT3 Pathway Translation in Onco

  2026-07-02

  This thought-leadership article explores the mechanistic precision and translational opportunities of Niclosamide (5-chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxybenzamide) as a STAT3 and NF-κB inhibitor in cancer research. Emphasizing rigorous experimental protocols and strategic context, it guides translational researchers through the scientific rationale, competitive landscape, and clinical promise of integrating Niclosamide into advanced oncology studies, while drawing actionable lessons from adjacent domains such as anti-parasitic drug development.

• AT13387: Hsp90 Inhibitor Workflows for Cancer Biology Resear

  2026-07-01

  AT13387, a next-generation Hsp90 inhibitor from APExBIO, enables researchers to dissect oncogenic signaling and regulated cell death with precision. Explore advanced protocols, data-driven troubleshooting, and learn how recent insights into apoptosis and DAMP release can expand your cancer biology toolkit.

• Lipo3K Transfection Reagent: Enabling Advanced Nucleic Acid

  2026-07-01

  Explore how the Lipo3K Transfection Reagent empowers high-efficiency transfection of DNA, siRNA, and mRNA—even in difficult-to-transfect cells. This article delves into its mechanistic advantages, connects new nucleic acid design insights, and guides practical adoption for next-generation gene expression and RNA interference research.

• Antifungal Imidazoles Target CpAdhE in Cryptosporidium parvu

  2026-06-30

  This study identifies antifungal imidazoles as potent, low micromolar inhibitors of the bifunctional aldehyde/alcohol dehydrogenase (CpAdhE) in Cryptosporidium parvum, a pathogen with limited treatment options. The findings demonstrate a novel drug target and highlight the efficacy of targeted compound screening for anti-cryptosporidial discovery.

• Synergistic Suppression of Pancreatic Tumor Growth via CDK4/

  2026-06-30

  Gu et al. (2025) demonstrate that combined inhibition of CDK4/6 and BET proteins synergistically suppresses pancreatic ductal adenocarcinoma (PDAC) growth and reverses epithelial-to-mesenchymal transition (EMT) by modulating the GSK3β-mediated Wnt/β-catenin pathway. Their work offers mechanistic insight into targeting tumor proliferation and invasion, informing future combinatorial strategies for PDAC therapy.

• iTBS Improves Motor Coordination and Autophagy in SCA3 Mice

  2026-06-29

  This study demonstrates that intermittent theta-burst stimulation (iTBS) significantly enhances motor coordination and modulates neuroinflammatory and autophagic pathways in a transgenic mouse model of spinocerebellar ataxia type 3 (SCA3/MJD). The findings provide mechanistic insight into how non-invasive brain stimulation can address core disease features in SCA3, highlighting potential avenues for therapeutic development.

• RNASEH1-AS1 lncRNA as Prognostic Biomarker in Hepatocellular

  2026-06-29

  This study identifies the long non-coding RNA RNASEH1-AS1 as a novel prognostic and diagnostic biomarker in hepatocellular carcinoma (HCC). Through integrative bioinformatic and experimental approaches, the research provides mechanistic insight into RNASEH1-AS1’s oncogenic roles and its potential as a therapeutic target.

• REC8 Stabilizes MAVS and STING to Boost Antiviral Innate Imm

  2026-06-28

  This study uncovers a novel role for the meiosis-associated protein REC8 in antiviral defense, showing that REC8 stabilizes the key adaptors MAVS and STING to enhance type I interferon responses. These insights expand our understanding of cGAS-STING pathway regulation and suggest new angles for investigating innate immunity.

• GSK J4 HCl: JMJD3 Inhibitor Applications in Epigenetic Resea

  2026-06-27

  GSK J4 HCl stands out as a potent, cell-permeable JMJD3 inhibitor, enabling advanced studies in histone demethylation and inflammation. This guide translates cutting-edge reference findings and real-world workflows into actionable protocols and troubleshooting tips for epigenetic and immunological research.

• QPRT Enhances Breast Cancer Invasion via MLCK–MLC Phosphoryl

  2026-06-26

  Liu et al. (2021) reveal that quinolinate phosphoribosyltransferase (QPRT) promotes breast cancer cell invasiveness by elevating myosin light chain (MLC) phosphorylation through the myosin light chain kinase (MLCK) pathway. This mechanistic insight establishes the QPRT–MLCK–MLC axis as a potential target for limiting metastasis in breast cancer models.

• Applied Use of 5-Aminolevulinic acid HCl in Heme Biosynthesi

  2026-06-26

  5-Aminolevulinic acid HCl enables precise modeling of heme biosynthesis and immune evasion in infection biology. Its high purity and solubility make it ideal for dissecting host-pathogen interactions, especially in studies targeting macrophage phagocytosis resistance mechanisms.

• Applied ABT-199 (Venetoclax) Workflows in Apoptosis Research

  2026-06-25

  ABT-199 (Venetoclax) redefines selectivity in apoptosis assays, enabling precise interrogation of Bcl-2-dependent pathways in hematologic malignancies. This article delivers advanced experimental workflows, troubleshooting strategies, and evidence-backed protocol enhancements for reliable, interpretable results in non-Hodgkin lymphoma and AML research.

• Pseudo-UTP: Advancing mRNA Synthesis with Pseudouridine Modi

  2026-06-25

  Pseudo-UTP delivers superior RNA stability, translation efficiency, and reduced immunogenicity, powering next-generation mRNA synthesis for vaccine and gene therapy workflows. This guide details advanced use-cases, protocol upgrades, and troubleshooting strategies—driven by real-world studies and expert insights.

• Hypoxia-Activated Photomolecular Glues: Synergistic Cyclin K

  2026-06-24

  This study introduces BNNC, a hypoxia-activated photomolecular glue designed to synergistically degrade Cyclin K and induce phototherapeutic DNA damage specifically in tumor microenvironments. The findings highlight enhanced tumor selectivity, increased apoptosis, and improved antitumor efficacy, with direct implications for the rational design of safer, more effective cancer treatments.

11694 records 1/780 page Next 12345 下5页 Last page